Regarding lncRNAs in PD patient biofluids, the downregulation of lncRNAs MEG3 was reported as a potential PD biomarker in the plasma of PD patients when compared to that of healthy individuals, being associated with the aggravation of non-motor symptoms, cognitive decline, and PD stage [183]. This evidence concerns the gene MEG3 and Parkinson disease.